NICE - Endorsed Technology Appraisals 2016/2017

It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.

Technology Appraisals Endorsement Process

The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland. The new arrangements are detailed in following circulars, which is effective from 18th December 2013;

NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13

For information, details of the previous arrangement can be found on the following circular;

NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11

2016/2017

The following technology appraisals have been endorsed during 2016/17. Information on technology appraisals endorsed in previous years can be found on the homepage.

Fully Endorsed

March 2017

NICE TA 432 - Everolimus for advanced renal cell carcinoma after previous treatment
- This guidance updates and replaces NICE Technology Appraisal TA219, which was endorsed by the DoH in December 2011.
NICE TA 433 – Apremilast for treating active psoriatic arthritis
- This guidance updates and replaces NICE Technology Appraisal TA372, which was endorsed by the DoH in January 2016.

February 2017

NICE TA 427 - Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (review of TA338)
- This guidance updates and replaces NICE Technology Appraisal TA338, which was endorsed by the DoH in May 2015.
NICE TA 428 - Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
NICE TA 429 - Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation.
NICE TA 430 - Sofosbuvir-Velpatasvir for Treating Chronic Hepatitis C.
NICE TA 431 - Mepolizumab for Treating Severe Refractory Eosinophilic Asthma. Note this guidance has been updated and replaced by TA671 - Mepolizumab for treating severe eosinophilic asthma, which was endorsed by the DoH in March 2021.

January 2017

NICE TA 421 - Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
- This guidance updates and replaces NICE Technology Appraisal TA295, which was endorsed by the DoH in September 2013.
NICE TA 422 - Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
- This guidance updates and replaces NICE Technology Appraisal TA296, which was endorsed by the DoH in October 2013.
NICE TA 423 - Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
- This guidance updates and replaces NICE Technology Appraisal TA250, which was endorsed by the DoH in May 2012.
NICE TA 424 - Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
NICE TA 425 - Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
- This guidance updates and replaces NICE Technology Appraisal TA241, which was endorsed by the DoH in February 2012 and partially updates TA70, which was endorsed by the DoH in March 2012.
NICE TA 426 - Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
- This guidance updates and replaces NICE Technology Appraisal TA251, which was endorsed by the DoH in May 2012 and partially updates TA70, which was endorsed by the DoH in March 2012.
NICE TA 427 - Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (review of TA338)
- This guidance updates and replaces NICE Technology Appraisal TA338, which was endorsed by the DoH in May 2015.

December 2016

NICE TA 417 - Nivolumab for treated or metastatic renal cell carcinoma
NICE TA 418 - Dapagliflozin in triple therapy for treating type 2 diabetes
- This guidance updates and replaces recommendation 1.3 of NICE Technology Appraisal TA288, which was endorsed by the DoH in July 2013.
NICE TA 419 - Apremilast for treating moderate to severe plaque psoriasis
- This guidance updates and replaces NICE Technology Appraisal TA368, which was endorsed by the DoH in December 2015.
NICE TA 420 - Ticagrelor for secondary prevention of atherothrombotic events after myocardial infarction

November 2016

October 2016

September 2016

NICE TA 401 - Bosutinib for previously treated chronic myeloid leukaemia
- This guidance updates and replaces TA 299, which was endorsed by the DoH in December 2013.
NICE TA 402 - Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer
- This guidance updates and replaces TA 309, which was endorsed by the DoH in May 2014.
NICE TA 403 - Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
NICE TA 404 - Degarelix for treating advanced hormone-dependent prostate cancer
NICE TA 405 - Trifluridine–tipiracil for previously treated metastatic colorectal cancer

August 2016

July 2016

‘Note this guidance has been updated and replaced by TA752 - Belimumab for treating active autoantibody-positive systemic lupus erythematosus, which was endorsed by the DoH in January 2022’.